benserazide
E804591
antiparkinsonian agent
aromatic L-amino acid decarboxylase inhibitor
peripheral dopa decarboxylase inhibitor
pharmaceutical drug
Benserazide is a peripheral dopa decarboxylase inhibitor used in combination with levodopa to enhance its effectiveness and reduce side effects in the treatment of Parkinson’s disease.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Benserazide | 0 |
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
antiparkinsonian agent
ⓘ
aromatic L-amino acid decarboxylase inhibitor ⓘ peripheral dopa decarboxylase inhibitor ⓘ pharmaceutical drug ⓘ |
| actsOnEnzyme | dopa decarboxylase ⓘ |
| commonAdverseEffect |
diarrhea
ⓘ
dyskinesia when combined with levodopa ⓘ nausea ⓘ orthostatic hypotension ⓘ vomiting ⓘ |
| contraindication |
concomitant use with non-selective MAO inhibitors
ⓘ
narrow-angle glaucoma ⓘ severe hepatic impairment ⓘ severe renal impairment ⓘ |
| crossesBloodBrainBarrier | no ⓘ |
| developedFor | enhancing levodopa therapy in Parkinson’s disease ⓘ |
| eliminationRoute | renal ⓘ |
| hasATCCode | N04BA02 ⓘ |
| hasBioavailability | low ⓘ |
| hasCASNumber | 322-35-0 ⓘ |
| hasChEMBLID | CHEMBL1082 ⓘ |
| hasChemicalFormula | C10H15N3O5 ⓘ |
| hasDrugBankID | DB01232 ⓘ |
| hasHalfLife | approximately 1.5 hours ⓘ |
| hasIUPACName | (2S)-2-amino-3-hydroxy-N'-[(2S,3R)-2,3,4-trihydroxy-3-(hydroxymethyl)butyl]propanediamide ⓘ |
| hasMolarMass | 257.246 g/mol ⓘ |
| hasPregnancyCategory | C (varies by jurisdiction) ⓘ |
| hasProteinBinding | low ⓘ |
| hasPubChemCID | 2327 ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasUNII | P8G79501I4 ⓘ |
| isComponentOf |
Madopar
NERFINISHED
ⓘ
Prolopa NERFINISHED ⓘ co-beneldopa ⓘ |
| legalStatusInAustralia | prescription only ⓘ |
| legalStatusInCanada | prescription only ⓘ |
| legalStatusInEuropeanUnion | prescription only ⓘ |
| legalStatusInUnitedStates | not approved ⓘ |
| mechanismOfAction | inhibits peripheral aromatic L-amino acid decarboxylase ⓘ |
| metabolism | hepatic ⓘ |
| primaryEffect |
increases availability of levodopa to the brain
ⓘ
reduces peripheral conversion of levodopa to dopamine ⓘ |
| reducesAdverseEffect |
cardiovascular side effects of levodopa
ⓘ
nausea ⓘ vomiting ⓘ |
| reducesSideEffectsOf | levodopa ⓘ |
| therapeuticUse |
treatment of Parkinson’s disease
ⓘ
treatment of parkinsonism ⓘ |
| usedInCombinationWith | levodopa NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.